title: The choice of recipient does not have a bearing on early outcome in liver transplant patients receiving grafts from non-heart-beating donors: a reappraisal?
abstract: BACKGROUND
  Donation after cardiac death has reemerged as a potential way of increasing the supply of organs for transplantation. We retrospectively reviewed the outcomes of non-heart-beating donor (NHBD) liver transplantation (OLT) experience and compared with standard heart-beating donation (HBD) at a single center.
  
  
  METHODS
  From October 2003 to November 2006, 13/111 liver transplantations were performed in our institution with NHBD. Living donor liver transplantation, splitting procedures, combined, and pediatric liver transplantations were excluded from this analysis.
  
  
  RESULTS
  Donor population was similar in both groups. The median warm ischemia time was 10 minutes (range 6 to 38). The median cold ischemia times 6 hours and 16 minutes (2.4 to 6.30 hours and 9 hours and 14 minutes (2.15 to 15.35 hours) for NHBD and HBD groups, respectively (P = .0002). In the NHBD groups, 4/13 (31%) grafts were retransplanted within 3 months, due to ischemic biliary lesions with severe cholestasis (n = 3) or due to the occurrence of primary nonfunction (n = 1). The retransplantation rate was significantly lower in the HBD group (11/98, 11%; P = .03). One-year patient and graft survivals were 62% and 54% versus 86% and 79%, respectively, for the NHBD and HBD groups (P = .107 and P = .003).
  
  
  CONCLUSIONS
  Liver grafts procured from donors after cardiac death accounted for a significantly greater retransplantation rates, mainly due to nonanastomotic biliary strictures. This risk must be taken into account when transplanting such grafts. Based upon this experience, NHBD cannot rival HBD to be a comparable source of quality organs for liver transplantation.
authors.affiliation: Department of General Surgery, Hepatobiliary and Liver Transplantation Service, Ghent University Hospital Medical School, De Pintelaan 185, 9000 Ghent, Belgium.
authors.forename: M-C
authors.initials: MC
authors.lastname: Dezza
authors.forename: F
authors.initials: F
authors.lastname: Berrevoet
authors.forename: M
authors.initials: M
authors.lastname: Sainz-Barriga
authors.forename: A
authors.initials: A
authors.lastname: Rossetto
authors.forename: L
authors.initials: L
authors.lastname: Colenbie
authors.forename: I
authors.initials: I
authors.lastname: Haentjens
authors.forename: H
authors.initials: H
authors.lastname: Van Vlierberghe
authors.forename: I
authors.initials: I
authors.lastname: Colle
authors.forename: J
authors.initials: J
authors.lastname: Van Huysse
authors.forename: M
authors.initials: M
authors.lastname: Praet
authors.forename: X
authors.initials: X
authors.lastname: Rogiers
authors.forename: B
authors.initials: B
authors.lastname: de Hemptinne
authors.forename: R
authors.initials: R
authors.lastname: Troisi
mesh_terms: D001663:Bilirubin / Q000097:blood; D015992:Body Mass Index; D003404:Creatinine / Q000097:blood; D016757:Death, Sudden, Cardiac; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data* / Q000600:supply & distribution*; D016896:Treatment Outcome
chemical_list: D003404:Creatinine; D001663:Bilirubin